Acalabrutinib Regimens Improve PFS in Treatment-Naïve Patients with CLL
December 8th 2019Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia